PPBT: שווי חברה לרווח נקי Purple Biotech Ltd

The asset valuation chart on GURU.Markets shows a P/E ratio of -0.10 for Purple Biotech (PPBT). The business relies on an office-based work format and external research centers. Purple Biotech (PPBT) attracts PhD scientists to combat tumor resistance through the use of stock option programs. Growth is driven by the development of CM24 and NT219, as well as partnerships in pancreatic cancer treatment.

The P/E ratio reflects the market value of a single unit of net profit, determining the investment payback period. An increase in this metric signals expectations of expansion, while a sharp decline indicates systemic risks. By analyzing P/E valuation trends, an investor diagnoses the fundamental stability of the business. For Purple Biotech (PPBT), this indicator is critical due to antibody development costs. Scientific potential in combating tumor resistance determines future capitalization.